Christoph Baumgärtel

Christoph Baumgärtel

Auto-generated profile, based on publicly available information

Christoph Baumgärtel

AGES Austrian Medicines and Medical Devices Agency, Austrian Federal Office for Safety in Health Care, 1200 Vienna, Austria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
BGBrian Godman
Brian Godman
AFAlexander E Finlayson
Alexander E Finlayson
PCParneet K Cheema
Parneet K Cheema
EZEva Zebedin-Brandl
Eva Zebedin-Brandl
IGIñaki Gutiérrez-Ibarluzea
Iñaki Gutiérrez-Ibarluzea
LGLars L Gustafsson
Lars L Gustafsson
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

1 January 2013 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RMRickard Malmstrom
Rickard Malmstrom
BGBrian Godman
Brian Godman
EDEduard Diogene
Eduard Diogene
CBChristoph Baumgärtel
Christoph Baumgärtel
MBMarion Bennie Marion Bennie
Marion Bennie Marion Bennie
LGLars L. Gustafsson
Lars L. Gustafsson
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use. Objective: To (i) review authority activities in over 30 countries and regions, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications for all major stakeholder groups. Methodology: Descriptive review and appraisal of activities regarding dabigatran and the development of guidance for groups through an iterative process. Results: There has been a plethora of activities among authorities to manage the prescribing of dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities. Conclusion: Models for introducing new drugs are essential to optimize their prescribing especially where there are concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.

Verified
Journal Article
Open access
PDF file
AFAndré Farkouh
André Farkouh
CBChristoph Baumgärtel
Christoph Baumgärtel
RGRoman Gottardi
Roman Gottardi
MHMargit Hemetsberger
Margit Hemetsberger
MCMartin Czejka
Martin Czejka
Alexandra Kautzky-WillerAlexandra Kautzky-Willer
Alexandra Kautzky-Willer
There is increasing evidence of sex differences in the action of anti-inflammatory drugs, with women being at significantly higher risk of adverse effects. Nevertheless, clinicians’ awareness of the implications of these sex differences on dosing and adverse event monitoring in routine practice is still in need of improvement. We reviewed the literature evaluating sex differences in terms of pharmacokinetics and pharmacodynamics of anti-inflammatory drugs. The anti-thrombotic activity of selective and non-selective COX-inhibitors tends to be stronger in men than women. Side effect profiles differ with regards to gastro-intestinal, renal and hepatic complications. Glucocorticosteroids were found to be more effective in men; women were more sensitive to corticosteroids when their oestradiol levels were high, a finding important for women taking hormonal contraception. TNF-alpha inhibitors have a longer half-life in men, leading to stronger immunosuppression and this a higher incidence of infections as side effects. Although research on sex differences in the effectiveness and safety of drugs is increasing, findings are often anecdotal and controversial. There is no systematic sex-differentiated reporting from clinical trials, and women are often under-represented. As personalized medicine is gaining in importance, sex, and gender aspects need to become integral parts of future research and policy making.

20 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AFAndré Farkouh
André Farkouh
MHMargit Hemetsberger
Margit Hemetsberger
CNChristian Noe
Christian Noe
CBChristoph Baumgärtel
Christoph Baumgärtel
Evidence-based pain therapy should rely on precisely defined and personalized criteria. This includes balancing the benefits and risks not only of single drugs but often requires complex between-drug comparisons. Non-steroidal anti-inflammatory drugs (NSAIDs) have been available for several decades and their use is described in an abundance of guidelines. Most of these guidelines recommend that ‘the selection of a particular NSAID should be based on the benefit-risk balance for each patient’. However, head-to-head studies are often lacking or of poor quality, reflecting the lower standards for clinical research and regulatory approval at the time. The inconsistency of approved indications between countries due to national applications adds to the complexity. Finally, a fading research interest once drugs become generic points to a general deficit in the post-marketing evaluation of medicines. Far from claiming completeness, this narrative review aimed to illustrate the challenges that physicians encounter when trying to balance benefits and risks in a situation of incomplete and inconsistent data on longstanding treatment concepts. Ibuprofen and mefenamic acid, the most frequently sold NSAIDs in Austria, serve as examples. The illustrated principles are, however, not specific to these drugs and are generalizable to any comparison of older drugs in daily clinical practice.

15 September 2015 in Generics and Biosimilars Initiative Journal
Verified
Journal Article
Closed access
BGBrian Godman
Brian Godman
MWMichael Wilcock
Michael Wilcock
AMAndrew Martin
Andrew Martin
SBScott Bryson
Scott Bryson
CBChristoph Baumgärtel
Christoph Baumgärtel
RMRickard Malmstrom
Rickard Malmstrom